The extent of adverse remodeling is directly associated with the risk of hospitalization and mortality.[14] Additionally, the LVEF plays a crucial role in evaluating the severity of impaired cardiac systolic function and guiding the management of diverse cardiovascular disorders.[15] A meta-analysis study suggest that the use of SGLT2 inhibitors resulted in significant improvements in LV regression, including LV mass (LVM), LVEF, LVEDV and LVESV. This evidence concerns the gene SLC5A2 and cardiovascular disorder.